Compare Crispr Therapeutics AG (CRSP) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Stanley Black & Decker, Inc. — how do they compare? Crispr Therapeutics AG trades at $53.42 (market cap $4.88B), while Stanley Black & Decker, Inc. trades at $88.68 (market cap $13.47B). The key difference: Stanley Black & Decker, Inc. is far larger — about 2.8× Crispr Therapeutics AG's market cap, and Stanley Black & Decker, Inc. pays a 3.77% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Stanley Black & Decker, Inc. for 62 Days on average.
| CRSP | SWK | |
|---|---|---|
Market Cap | $4.88B | $13.47B |
Volume | 2,861,747 | 2,859,744 |
Sector | Health | Industrials |
52-Week High | $74.92 | $104.00 |
52-Week Low | $44.34 | $62.12 |
Typical Hold Time | 77 Days | 62 Days |
Enterprise Value | $3.30B | $17.63B |
Dividend Yield | — | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
Stanley Black & Decker (SWK) trades at $88.49, up 0.2% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with Q2 2026 EPS of $1.57 beating expectations of $1.21, and projected 2026 net income margin of 4.06%. Valuation metrics appear reasonable with P/E of 21.8 and P/S of 0.89. Recent news highlights new product launches and dividend consistency as a Dividend King.
SWK presents a mixed outlook with strong brand positioning and margin improvement initiatives offset by technical weakness. The consensus price target of $93.00 suggests 5% upside potential, but investors face execution risks amid competitive pressures and ongoing operational challenges. The stock's dividend history provides income stability while awaiting fundamental improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
